Trial reportThe American journal of psychiatry2016
Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.
Registry-linked trialAbstract readClinical TrialLetter
In one paragraph
Trial report in The American journal of psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02267629 (Open Label Trial of Rapastinel), which is not on this map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Who cites it
14 citing papers in PubMed.
- Trial
- Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.Molecular autism · 2021Trial
- Excitatory Amino Acid Transporters as Therapeutic Targets in the Treatment of Neurological Disorders: Their Roles and Therapeutic Prospects.Neurochemical research · 2025Review
- NMDAR modulators as rapid antidepressants: Converging and distinct signaling mechanisms.Integrative clinical medicine · 2020Article
- Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.Journal of experimental pharmacology · 2020Review
- Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.The international journal of neuropsychopharmacology · 2019Article
- The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder.Frontiers in pharmacology · 2019Review
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
- Pregenual Anterior Cingulate Dysfunction Associated with Depression in OCD: An Integrated Multimodal fMRI/Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.The international journal of neuropsychopharmacology · 2018Article
- GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.Frontiers in molecular neuroscience · 2018Article
- Modulation of the activity ofNeuropsychiatric disease and treatment · 2017Review
- Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.The Journal of clinical psychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Carolyn I RodriguezFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Jordana ZwerlingFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Eyal KalanthroffFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Hanyang ShenFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Maria FilippouFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Booil JoFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Helen Blair SimpsonFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Ronald M BurchFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Joseph R MoskalFrom the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.
Funding
Novel Interventions for Adults with Obsessive-Compulsive DisorderK23MH092434 · NIMH · STANFORD UNIVERSITY · PI RODRIGUEZ, CAROLYN I · 2011 to 2015
$805kEnhancing Patient-Oriented Research and Training in OCDK24MH091555 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SIMPSON, HELEN BLAIR · 2010 to 2014
$742kNIMH NIH HHS K23 MH092434NIMH NIH HHS K24 MH091555
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultHumansMiddle AgedObsessive-Compulsive DisorderOligopeptidesPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateTreatment OutcomeYoung AdultGLYX-13 peptideOligopeptidesReceptors, N-Methyl-D-AspartateAMPAClinical Drug StudiesGLYX-13KetamineNMDAObsessive-Compulsive DisorderOCDRapastinel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02267629ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.